Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2021-07-01 DOI:10.1053/j.ackd.2021.04.005

Ofri Mosenzon , Meir Schechter , Gil Leibowitz

{"title":"Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes","authors":"Ofri Mosenzon , Meir Schechter , Gil Leibowitz","doi":"10.1053/j.ackd.2021.04.005","DOIUrl":null,"url":null,"abstract":"<div><p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). These medications effectively reduce cardiovascular (CV) risk in patients with T2D and established CV disease or with multiple risk factors. In addition, treatment with GLP-1 RA may exert protective effects on the diabetic kidney. Herein, we summarize the findings regarding the kidney safety and efficacy of GLP-1 RAs in patients with T2D. We review data from GLP-1 RAs phase 3 kidney studies, CV outcome trials, as well as real-world evidence. The accumulating data show that treatment with GLP-1 RAs is safe, well-tolerated, and effective in patients with different levels of kidney dysfunction. Furthermore, CV outcome trials suggest that GLP-1 RAs reduce albuminuria and may attenuate the decline in kidney function over time. The ongoing FLOW trial studying the effects of semaglutide in patients with diabetic kidney disease is expected to shed light on the effects of GLP-1 RAs on kidney outcomes and clarify their role in the management of patients with T2D and kidney disease.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1548559521000380/pdfft?md5=258c753d4cb626b81de4603db7a133c3&pid=1-s2.0-S1548559521000380-main.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1548559521000380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 4

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective in reducing glycemia in patients with type 2 diabetes (T2D). These medications effectively reduce cardiovascular (CV) risk in patients with T2D and established CV disease or with multiple risk factors. In addition, treatment with GLP-1 RA may exert protective effects on the diabetic kidney. Herein, we summarize the findings regarding the kidney safety and efficacy of GLP-1 RAs in patients with T2D. We review data from GLP-1 RAs phase 3 kidney studies, CV outcome trials, as well as real-world evidence. The accumulating data show that treatment with GLP-1 RAs is safe, well-tolerated, and effective in patients with different levels of kidney dysfunction. Furthermore, CV outcome trials suggest that GLP-1 RAs reduce albuminuria and may attenuate the decline in kidney function over time. The ongoing FLOW trial studying the effects of semaglutide in patients with diabetic kidney disease is expected to shed light on the effects of GLP-1 RAs on kidney outcomes and clarify their role in the management of patients with T2D and kidney disease.

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂治疗2型糖尿病患者的肾脏预后

胰高血糖素样肽-1受体激动剂(GLP-1 RAs)在降低2型糖尿病(T2D)患者血糖方面非常有效。这些药物有效地降低了t2dm患者心血管(CV)的风险，并确定了心血管疾病或有多种危险因素。此外，GLP-1 RA治疗可能对糖尿病肾脏有保护作用。在此，我们总结了关于GLP-1 RAs在T2D患者肾脏安全性和有效性的研究结果。我们回顾了GLP-1 RAs 3期肾脏研究、CV结局试验以及真实世界证据的数据。越来越多的数据表明，GLP-1 RAs治疗不同程度肾功能不全患者是安全、耐受性良好且有效的。此外，CV结果试验表明，GLP-1 RAs可减少蛋白尿，并可能随着时间的推移减轻肾功能的下降。正在进行的FLOW试验研究西马鲁肽对糖尿病肾病患者的影响，预计将揭示GLP-1 RAs对肾脏预后的影响，并阐明它们在T2D和肾病患者管理中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464